Publication:
Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?

Simple item page
dc.contributor.authorKocaturk E.
dc.contributor.authorBÜLBÜL BAŞKAN E.
dc.contributor.authorSU KÜÇÜK Ö.
dc.contributor.authorOzdemir M.
dc.contributor.authorOrnek S.
dc.contributor.authorCan P. K.
dc.contributor.authorHasal E.
dc.contributor.authorENGİN B.
dc.contributor.authorAtakan N.
dc.contributor.authorALPSOY E.
dc.contributor.institutionauthorSU KÜÇÜK, ÖZLEM
dc.date.accessioned2023-01-08T21:49:07Z
dc.date.available2023-01-08T21:49:07Z
dc.date.issued2022-09-01
dc.description.abstractBackground: Chronic Spontaneous Urticaria (CSU) is characterized by recurrent wheals and/or angioedema for longer than 6-weeks. Guidelines recommend Omalizumab (Oma) as first-line and Cyclosporine-A (Cs-A) as second-line treatment in antihistamine resistant CSU. This step-wise algorithm might be time-consuming and costly.
dc.identifier.citationKocaturk E., BÜLBÜL BAŞKAN E., SU KÜÇÜK Ö., Ozdemir M., Ornek S., Can P. K., Hasal E., ENGİN B., Atakan N., ALPSOY E., "Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?", ANAIS BRASILEIROS DE DERMATOLOGIA, cilt.97, sa.5, ss.592-600, 2022
dc.identifier.doi10.1016/j.abd.2022.03.003
dc.identifier.endpage600
dc.identifier.issn0365-0596
dc.identifier.issue5
dc.identifier.pubmed35853771
dc.identifier.startpage592
dc.identifier.urihttps://hdl.handle.net/20.500.12645/34604
dc.identifier.volume97
dc.relation.ispartofANAIS BRASILEIROS DE DERMATOLOGIA
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectDermatoloji
dc.subjectSağlık Bilimleri
dc.subjectMedicine
dc.subjectInternal Medicine Sciences
dc.subjectDermatology
dc.subjectHealth Sciences
dc.subjectDERMATOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectDERMATOLOGY
dc.subjectCLINICAL MEDICINE
dc.subjectClinical Medicine (MED)
dc.subjectBiomarker
dc.subjectChronic urticaria
dc.subjectCyclosporine
dc.subjectOmalizumab
dc.subjectBIOMARKERS
dc.titleOmalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?
dc.typeArticle
dspace.entity.typePublication
local.avesis.id05dfe602-86d4-40aa-b185-298b366d3a48
local.indexed.atPubMed
relation.isAuthorOfPublicationfd8dc121-9bbe-4ee4-a2fd-5e237676169d
relation.isAuthorOfPublication.latestForDiscoveryfd8dc121-9bbe-4ee4-a2fd-5e237676169d

Files

Collections

Yayınlar - Eserler